XBiotech Enrolls Final Patient in Phase I Portion of Clinical Study to Evaluate Antibody Treatment for Staphylococcus Aureus

XBiotech (NASDAQ:XBIT) announced the completion of enrollment in the Phase I portion of the ongoing clinical study to evaluate its antibody treatment for Staphylococcus aureus (S. aureus) infections. The Company is developing a True Human™ antibody to treat serious, blood-borne infections caused by S. aureus including methicillin-resistant (MRSA) strains.
According to the news:

XBiotech’s novel antibody therapy, known as 514G3, was developed from a human donor with natural antibodies effective at neutralizing MRSA and non-MRSA forms of S. aureus. 514G3 knocks out the principle immune evasion mechanism of the bacteria, allowing white blood cells to detect and destroy the bacteria. 514G3 is expected to treat all strains of MRSA and can be used without consideration for strain-specific resistance to various antibiotics. As a True Human monoclonal antibody, 514G3 is expected to be well tolerated without the side effects or risks of antibiotics.

Michael Stecher, M.D., XBiotech’s Medical Director, said:

S. aureus is a major disease problem worldwide and we are encouraged by the advancement of 514G3 in the clinic. We are committed to develop this therapy as expeditiously as possible to address the growing unmet need worldwide for a treatment against these deadly infections.

Click here to view the full press release.